Patient-derived olfactory mucosa for study of the non-neuronal contribution to amyotrophic lateral sclerosis pathology

Vega García-Escudero a, b, María Rosales a, José Luis Muñoz c, Esteban Scola d, Javier Medina d, Hena Khalique a, Guillermo Garaulet a, Antonio Rodríguez a, Filip Lim a, *

a Departamento de Biología Molecular, Universidad Autónoma de Madrid, Madrid, Spain
b Centro de Biología Molecular “Severo Ochoa” (C.S.I.C.- U.A.M.), Universidad Autónoma de Madrid, Madrid, Spain
c Departamento de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
d Departamento de Otorrinolaringología, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Received: May 22, 2014; Accepted: October 10, 2014

Abstract

Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disease which currently has no cure. Research using rodent ALS models transgenic for mutant superoxide dismutase 1 (SOD1) has implicated that glial–neuronal interactions play a major role in the destruction of motor neurons, but the generality of this mechanism is not clear as SOD1 mutations only account for less than 2% of all ALS cases. Recently, this hypothesis was backed up by observation of similar effects using astrocytes derived from post-mortem spinal cord tissue of ALS patients which did not carry SOD1 mutations. However, such necropsy samples may not be easy to obtain and may not always yield viable cell cultures. Here, we have analysed olfactory mucosa (OM) cells, which can be easily isolated from living ALS patients. Disease-specific changes observed when ALS OM cells were co-cultured with human spinal cord neurons included decreased neuronal viability, aberrant neuronal morphology and altered glial inflammatory responses. Our results show the potential of OM cells as new cell models for ALS.

Keywords: olfactory mucosa • amyotrophic lateral sclerosis • non-cell autonomous toxicity • SOD-1 neurotoxicity • inflammation-responsive promoter

Introduction

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a neurodegenerative disorder of unknown origin characterized by progressive degeneration of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and the spinal cord, initiating in mid-age life [1]. It results in muscle paralysis and ultimately death because of respiratory failure, most commonly within 3–5 years of diagnosis [2].

The classical division of ALS into familial or sporadic types has been made depending on patient family history. Approximately, 90% of ALS patients are considered sporadic (sALS) as they appear to occur randomly throughout the community, whereas the remaining 10% are familial (fALS) cases [3], showing autosomal dominant inheritance in the majority of instances. Of these, ~12% are associated with mutations in the Cu/Zn superoxide dismutase (SOD-1) gene [4], which seem to confer toxic gain of an unknown function rather than loss of normal SOD1 activity [5]. Other genes, including TARDBP (TAR DNA-binding protein 43) [6], FUS (fused in sarcoma) [7, 8] and angiogenin (ANG) [9] have also been implicated in fALS. Recently, a large GGGGCC repeat expansion in the first intron of the C9orf72 gene has been reported to be the most common genetic cause of ALS, accounting for approximately 40% of fALS and 7% of sALS [10–12]. Sporadic and familial ALS cases are however, clinically indistinguishable, suggesting similar underlying pathophysiological mechanisms of neurodegeneration.

While several pathogenic processes for the motor neuron degeneration observed in ALS have been proposed, one of the most prevailing hypotheses supports a non-cell autonomous process: neighbouring astrocytes are thought to play a major role in disease progression [13–18]. Nevertheless, the basis for the specificity of astrocytes and other glial cells in the selective degeneration of motor neurons remains unclear. Indeed, the molecular mechanisms...
underlying neuronal death in ALS are presently not fully determined and appear to be multifactorial. Glutamate excitotoxicity, mitochondrial dysfunction [19], accumulation of intracellular protein aggregates [20], oxidative stress [21], hypoxia [22, 23], alterations in RNA metabolism [24], impaired axonal transport [25], growth factor deficiency [26] and neuroinflammation [27] have all been proposed to be involved.

Evidence of inflammation is observed in post-mortem tissue [28–31], in cerebrospinal fluid [32, 33] and in blood samples [34] from fALS and sALS patients. These observations are in agreement with previous observations of neuroinflammation in rodent models of ALS [35, 36]. In transgenic mice expressing mutant SOD-1, increased levels of toll-like receptors (TLRs) are detected [37]. Microglial neurotoxic inflammatory responses have been suggested to be facilitated via TLR2 [38]. In addition, it has been shown that mutant SOD-1 binds to CD14, which is a co-receptor of TLR2 and TLR4, and that the microglial activation mediated by mutant SOD-1 can be attenuated using TLR2, TLR4 and CD14 blocking antibodies [39]. In accordance, Casula et al. have reported an up-regulation of TLR2 and TLR4 as well as other pro-inflammatory molecules such as Receptor for Advanced Glycation End products and High Mobility Group protein B1 in reactive glia in the spinal cord of sALS victims [30]. Unanswered question, however, is whether these correlative observations reflect a causal relationship, with inflammatory activation provoking ALS, or alternatively, ALS pathology triggering inflammatory responses.

A large amount of ALS research has made use of in vitro and in vivo models based on overexpression of genes with mutations linked to familial ALS. However, as 90% of ALS cases are sporadic, it is difficult to ascertain how representative these models are with respect to the human disease. This highlights one of the main obstacles currently limiting the study also of other neurological diseases: the need for patient-derived cell models that are relevant and robust enough to produce the large quantities of cells required for molecular and functional analyses. Current efforts on developing sALS models have used patient-derived samples from post-mortem brain, spinal cord and muscle [28, 40]. More recently, sALS patient-derived cell cultures have been developed including astrocytes differentiated from neural progenitor cells obtained from spinal cord necropsies [41], and induced pluripotent stem cells [42, 43]. All these models represent various degrees of compromise between relevance for understanding disease aetiology and suitability for diagnostics and drug discovery.

In this study, we have explored an alternative patient-derived neural model for the study of sALS disease: primary olfactory mucosa (OM) cultures derived from sporadic ALS patients. The OM is easily accessible for non-invasive biopsy in human adults [44]. Either biopsied tissue or derived primary cultures have been shown to exhibit alterations in Rett’s syndrome, Alzheimer’s disease, fragile X syndrome, schizophrenia, Parkinson’s disease and bipolar disorder with respect to healthy donors [45–50]. OM-derived primary cultures contain several types of extraepithelial cells including multipotent stem cells [51–54] as well as olfactory ensheathing glia [55] which normally support the growth of primary olfactory axons from the neuroepithelium in the nasal cavity to the brain [56]. These glia are present both in the peripheral as well as the central nervous system, and share characteristics of both astrocytes as well as Schwann cells. Moreover, OM-derived ensheathing glia have been used for therapeutic purposes in spinal cord injury [57, 58] and even in ALS [59–61]. The fact that OM transplants exhibit regenerative capacity in spinal cord [58], led us to speculate that the interaction of OM-derived cells with spinal cord-derived motor neurons may recapitulate the non-cell autonomous properties described for ALS.

It is conceivable that olfactory ensheathing cells (OECs) may share some similar characteristics of inflammatory cells, providing a degree of immunological protection against infections in the olfactory system. Indeed, microarray analysis has revealed that, relative to astrocytes and Schwann cells, OECs express higher levels of a number of innate immune factors, including lysosomes, chemokines and monocyte chemotactic proteins, suggestive of functions in modulating neuroinflammation [62]. OECs have also been demonstrated to express TLRs and possess the cellular machinery to respond to certain bacterial ligands [63, 64].

Another interesting aspect of using OM cells to model ALS is that it has been proposed that chemosensory impairment is an early symptom of many neurodegenerative diseases [65, 66], including ALS [67, 68]. The mucus covering olfactory epithelium has been shown to contain reduced levels of growth factors that may be related to this reduction in olfactory capacity [68]. Thus, this olfactory dys-function suggests that mucosa neuropathology components might also be affected in neurodegenerative disorders, supporting their use as disease models. Notably, disease-specific alterations in gene expression, protein expression and cell function have previously been found in primary OM cultures derived from patients with schizophrenia and Parkinson’s disease [69] as well as spastic paraplegia [70].

In this study, we propose the use of OM to model ALS, demonstrating their negative effect over motor neuron survival and morphology as well as the activation of inflammatory responses as a consequence of this deleterious interaction.

Materials and methods

Reagents and antibodies

All media such as Hank’s balanced salt solution (HBSS), HBSS supplemented with Ca²⁺ and Mg²⁺, DMEM, DMEM:F12 and Neurobasal medium as well as other cell culture reagents including L-Glutamine, TrypLE, bovine pituitary extract, B-27 supplement, N-2 supplement were purchased from Gibco, Life Technologies (Barcelona, Spain). Other special reagents used were: trypsin, penicillin, streptomycin, bovine serum albumin, trypan blue, retinoic acid and lipopolysaccharide (LPS), all purchased from Sigma-Aldrich (St. Louis, MO, USA); DNase I (Roche, Mannheim, Germany); foetal calf serum (FCS, Hyclone, Logan, UT, USA); forskolin (Alomone, Jerusalem, Israel); primocin (InvivoGen, San Diego, CA, USA); carboxyfluorescein succinimidyl ester (CFSE, Molecular Probes/Life Technologies, Eugene, OR, USA); brain-derived neurotrophic factor (BDNF, Santa Cruz Biotechnology, Santa Cruz, CA, USA), forskolin (Alomone Labs, Jerusalem, Israel); Smoothened agonist (SAG, Merck/Calbiochem, Darmstadt, Germany); Fluoromount-G (Southern Biotech, Birmingham, AL, USA); matrigel (BD Biosciences/Pharmin- gen, Madrid, Spain) and DAPI (Calbiochem, Nottingham, UK).
The antibodies against the following proteins were used: βIII-tubulin [71]; S100β, SOD-1 and GAPDH (from Sigma-Aldrich); GFAP and nestin (from Chemicon, Temecula, CA, USA, now part of Merk-Millipore, Darmstadt, Germany); vimentin (Boehringer, Ingelheim, Germany); p75 and neuroligin (from Santa Cruz Biotechnology). The secondary antibodies used were anti-rabbit, antimouse and anti-goat Alexa 555, and Alexa 488 (Molecular Probes/Life Technologies) for immunofluorescence and peroxidase-labelled secondary antibodies (Sigma-Aldrich) for Western blot.

Culture of patient-derived OM

Human OM primary cultures were obtained and cultured as previously described [72]. OM primary cultures were derived from human nasal endoscopic biopsies that were carried out by otolaryngologists (E. Scola and J. Medina) at the Gregorio Marañón Hospital, Madrid. Written informed consent was obtained from all healthy or ALS patients, and the study was approved by the Gregorio Marañón Hospital ethics committee. Pre- and post-nasal biopsy olfaction were evaluated in ALS patients and controls, according to the Barcelona Smell Test-24 (BAST-24), previously validated for the Spanish population [73]. No significant changes were found between the ALS patient group and controls, either before or after nasal biopsy. Briefly, tissue samples were kept at 4°C in HBSS until processing by disaggregation with 0.05% trypsin in HBSS for 20 min, inactivation with one volume of FCS, followed by a 5 min. treatment with 0.01% DNase-1 in HBSS supplemented with Ca²⁺ and Mg²⁺, after which the cell pellet was finally resuspended in ME medium: DMEM:F12 (1:1), 10% FCS, 2 mM glutamine, 20 μg/ml bovine pituitary extract, 2 μg/ml forskolin, 50 μg/ml prominoc. Unless specified, OM cells were grown as adherent monolayer cultures in ME medium.

Immunofluorescence assay

Immunofluorescence analysis was performed as previously described [68] using the primary and secondary antibodies detailed above and followed by 10 min. incubation with DAPI (1:500). Coverslips were mounted with Fluoromount-G according to the provider’s guidelines. Representative images were taken with an Axiovert200 (Zeiss, Oberko- chen, Germany) inverted microscope coupled to a CCD camera using Metavue 5.07 software (Universal Imaging, Bedford Hills, NY, USA).

Neuronal survival assay

Preparation of frozen stocks of differentiated neurons from human foetal spinal cord neural precursors was as previously described [76]. For co-cultures with patient-derived glia, OM samples were first seeded in six-well plates (10³ cells per well). After 24 hrs, differentiated neurons were thawed out and labelled with 25 μM CFSE in PBS containing 1% bovine serum albumin, for 15 min. at 37°C. After labelling, cells were diluted with 5 ml of neuronal medium [DMEM:F12 supplemented with B-27 (20 μg/ml), N-2 (10 μg/ml), streptomycin (100 U/ml) and penicillin (100 μg/ml)]. The cells were then centrifuged and resuspended in 3 ml of neuronal medium at 37°C. The percentage of live neurons was determined by trypan blue exclusion and the labelled cells were seeded in neuronal medium over OM monolayers at a neuron:OM ratio of 1:6. Culture medium was changed partially three times per week. After 2 weeks of co-culture cells were detached with TrypLE, washed with PBS and resuspended in 200 μl PBS for flow cytometry analysis. The total number of CFSE-positive cells was counted in 110 μl of each sample using a FACS CantoII flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA) and the results analysed using FlowJo software (TreeStar Inc., Ashland, OR, USA).

Olfactory mucosa survival assay

Olfactory mucosa cells were seeded in six-well plates (10⁵ cells/well). After 24 hrs, ME culture medium was substituted for neuronal medium (DMEM:F12 supplemented with 20 μg/ml B-27, 10 μg/ml N-2, 100 U/ml streptomycin and 100 μg/ml penicillin) after which the medium was renewed partially three times per week. Twenty-three days after seeding, cells were collected and the total number of surviving cells was counted in a FACS CantoII flow cytometer (Becton Dickinson Biosciences) and the results analysed using FlowJo software (TreeStar Inc.).

Neuronal morphology assay

Differentiation of human foetal spinal cord neural precursors along the motor neuron lineage was carried out by culturing them in Neurobasal medium supplemented with N-2 (5 μg/ml), BDNF (50 ng/ml), retinoic acid (100 nM), Forskolin (5 μM) and streptomycin/penicillin (100 U/ml and 100 μg/ml, respectively) during the first 4 days and Neurobasal medium similarly supplemented with N-2, BDNF, retinoic acid, streptomycin/penicillin, and SAG (100 nM) for up to 3 weeks. A subconfluent culture of OM cells was grown on round coverslips in 24 multi-well plates and differentiated neurons were seeded on top (5 × 10³ neurons per well) in Neurobasal medium supplemented with N-2 (5 μg/ml) and streptomycin/penicillin (100 U/ml and 100 μg/ml, respectively). The medium was changed partially three times per week. After 2 weeks of co-culture, cells were fixed with paraformaldehyde and immunofluorescence analysis was performed as previously described [75] using 195 antisera specific for βIII-tubulin [71] diluted 1:3000 during 1 hr followed by incubation with anti-rabbit Alexa 555 and DAPI. Representative images were taken and morphological quantification was performed by scoring a minimum of 15 βIII-tubulin-positive cells in at least nine random fields per condition into different morphologies: neuronal, when the cells exhibited filamentous βIII-tubulin staining and the length of the longest neurite was at least four times that of the longest axis of the nucleus; non-neuronal, when the βIII-tubulin stain was diffuse, cytoplasm was more expanded and its longer part was smaller than four times the size of longest axis of its corresponding nucleus. Cells not matching either morphology were discarded from the analysis.

Lentivirus production and titration

The viral vectors used to express wild-type and mutant SOD-1 were Lentisod1WT and Lentisod1G37R [18]. The inflammation-responsive lentivectors LV-NFκBp-luc, LV-ESSELECTp-luc, LV-IL1-IL6p-luc encode the luciferase-ires-GFP reporter construct under the control of 6× NFκB, E-selectin and IL1-IL6 hybrid promoters, respectively; the LV-SFFVp-luc lentivirus encodes the same reporter under the control of the SFFV constitutive promoter [74]. Lentiviral stocks were produced as previously described [75]. Vector titre was determined in OM cells by
infection with serial dilutions of the viral supernatants and the number of transduced cells determined 48 hrs post-infection by flow cytometry (FACScalibur, BD Biosciences) using GFP expression.

fALS cell model

The foetal human primary astrocyte cell line, HA1800, was obtained from ScienCell Research Laboratories (Carlsbad, CA, USA) and was cultured according to the provider’s instructions. These cells were infected with LentiSOD1<sup>wt</sup> and LentiSOD1<sup>G37R</sup> [18] before each experiment.

Innate immune response assay

Astrocytes and OM cells were infected with the indicated lentivectors 2 days after the treatment under study. For LPS stimulation, 24 hrs before treatment, cells were subjected to serum starvation by incubation overnight in DMEM containing 2% FCS to minimize interference by serum-borne factors. Cells were then cultured in the presence of LPS (500 ng/ml) in DMEM containing 2% FCS for the indicated period.

For co-culture, subconfluent spinal cord neural precursors were seeded in 96 multi-well plates coated with matrigel and differentiated along the motor neuron lineage by culture in Neurobasal medium supplemented with N-2 (5 μ/ml), BDNF (50 ng/ml), retinoic acid (100 nM), Forskolin (5 μM) and streptomycin/penicillin (100 U/ml and 100 μg/ml, respectively) during first 4 days and Neurobasal medium similarly supplemented with N-2, BDNF, retinoic acid, streptomycin/penicillin, and SAG (100 nM) during the last 5 days. Thereafter, OM cells and human astrocytes expressing SOD-1 (where indicated) and harbouring luciferase reporter constructs, were seeded on top of the neurons at a density of 7000 per well in Neurobasal medium supplemented with N-2 (5 μ/ml) and penicillin/streptomycin (100 U/ml and 100 μg/ml, respectively). Medium was changed every 2 days and luciferase assays were performed at the time indicated for each experiment.

Luciferase assay

Cells were washed with PBS and frozen at −80°C. Luciferase activity was measured with an AutoLumat LB953 luminometer (Berthold Technologies, Bad Wildbad, Germany) using a commercially available assay system (E1501; Promega, Madison, WI, USA) following the manufacturer’s instructions. All treatments were performed in triplicate. Normalized luciferase activity represented in the graphs was the result of dividing the relative light unit (RLU) values obtained for each inflammation-responsive vector by the mean RLU value obtained for the constitutive SFFV promoter vector under the same conditions.

Western blot assay

Cells were collected, washed and resuspended in lysis buffer (50 mM Tris-HCl pH 7.5; 300 mM NaCl; 0.5% sodium dodecyl sulphate and 1% Triton X-100) and incubated for 15 min. at 95°C. Protein concentration of the extracts was measured using the Dc protein assay kit (Bio-Rad, Hercules, CA, USA) and 30 μg of each cell extract was resolved by electrophoresis in 12% polyacrylamide gels in the presence of sodium dodecyl sulphate. After electrophoresis, proteins were transferred to nitrocellulose membranes which were blocked with 10% low-fat milk in PBS-T (0.3% TWEEN 20 in PBS) and incubated overnight at 4°C with specific primary antibody against SOD-1 (1:1000) and anti-GAPDH antibody (1:5000). After washing, membranes were incubated with peroxidase-labelled secondary antibodies and the immunoreactive proteins were visualized using the enhanced chemiluminescence detection kit Western Lightning Plus-ECL (PerkinElmer, Waltham, MA, USA) following the supplier’s instructions.

Statistical analysis

Statistical comparison of the data sets was performed with Student’s t-test. The differences are given with their corresponding P-value, which is the probability that the observed result could occur merely by chance under the null hypothesis.

Results

Co-culture of neurons with ALS mucosa cells diminishes their survival

As a result of the fact that the majority of ALS cases are not associated with a known mutation [21], our first goal was to generate an ALS cell bank based on sporadic cases. Numerous studies have highlighted the relevance of glial cells in ALS pathogenesis [13–18] and therefore we concentrated on OM as it is a source of glia that can be obtained from living patients via a small nasal endoscopic biopsy [72]. We generated a bank of OM from eight healthy donors and seven ALS patients (Table 1). In this study, we used culture conditions optimized to enrich for the growth of glia cells [72]; we successfully obtained primary cultures from all of the patients and did not detect any difference in the efficiency, survival, growth rates, life span or antigenic markers in samples derived from ALS patients compared to those from healthy donors (Figs S1 and S2, and Table 1). All cells were similar in their expression of the antigenic markers GFAP, vimentin, S100β, neurolgin, nestin and the low affinity NGF receptor p75 (Fig. S2), all of which are characteristic of OECs. However, as a cautionary note, our previous work has demonstrated that these immunocytochemical properties do not clearly distinguish OECs from other cell types such as fibroblasts or gliomas [72]. To test whether these biopsy-derived glia exhibit disease-specific neurotoxicity similar to that observed for spinal cord astrocytes derived from ALS patient cadavers, we co-cultured them with differentiated post-mitotic human spinal cord neurons [76] which we pre-labelled with CFSE to facilitate quantification. The neurons were plated over OM monolayers at a neuron:OM ratio of 1:6 (Fig. 1A) and after 2 weeks of co-culture, cells were harvested and the total number of surviving neurons was counted by flow cytometry. We observed that neuronal survival was significantly higher when the neurons were co-cultured with OM derived from healthy donors.
compared to when they were co-cultured with OM from ALS patients (Fig. 1B).

Neuron morphology is aberrant in co-cultures with OM from ALS patients

In addition to diminished survival when spinal cord neurons were co-cultured with OM cells from ALS patients, we observed that the morphology of the surviving cells was significantly affected (Fig. 2). While neurons grown over control OM cells preserved their typical morphology with a small cell body and long neurites positive for strong fibrillar βIII-tubulin staining (Fig. 2A, upper row), neurons grown over OM cells from ALS patients often displayed aberrant morphologies, exhibiting wider cell bodies and retracted neurites with less fibrillar and more diffuse βIII-tubulin staining (Fig. 2A, lower row). As OM cells may express low levels βIII-tubulin [72], we optimized the βIII-tubulin staining sensitivity to exclusively label CFSE-positive cells. For morphometric analysis, cells were scored as neuronal if the length of the longest neurite was at least four times that of the longest axis of the nucleus. Based on this criterion, the data showed a significant reduction in the percentage of cells with neuronal morphology when the neurons were co-cultured with OM from ALS patients compared to when they were co-cultured with OM from healthy donors. We thus concluded that co-culture with OM derived from ALS patients not only reduced neuronal survival but also modified the morphology of surviving cells.

Table 1 Information about olfactory mucosa donors

| Patient | Gender | Age | Maximum cell passage | Number of cells/mm² for confluence |
|---------|--------|-----|----------------------|-----------------------------------|
| C1      | Male   | 26  | 10                   | 260                               |
| C2      | Male   | 36  | >10                  | 364                               |
| C3      | Female | 51  | >10                  | 260                               |
| C16     | Male   | 20  | >10                  | 260                               |
| C17     | Female | 25  | >10                  | 260                               |
| C18     | Female | 22  | >10                  | 260                               |
| C19     | Male   | 29  | >10                  | 260                               |
| C20     | Female | 30  | >10                  | 364                               |
| ALS1    | Male   | 57  | >10                  | 208                               |
| ALS3    | Male   | 72  | 9                    | 364                               |
| ALS4    | Male   | 48  | >10                  | 208                               |
| ALS5    | Male   | 36  | 10                   | 208                               |
| ALS6    | Female | 61  | >10                  | 260                               |
| ALS7    | Male   | 40  | >10                  | 364                               |
| ALS8    | Male   | 39  | >10                  | 364                               |

Fig. 1 Spinal cord neuron survival after co-culture with olfactory mucosa (OM). (A) Scheme of the procedure using flow cytometry to study the survival of CFSE-labelled spinal cord neurons after co-culture with OM cells from healthy control or ALS donors. (B) Flow cytometry quantification of the number of CFSE-labelled surviving neurons after 2 weeks of co-culture with OM cells or in the absence of these cells (none). The left graph shows means and standard errors of the mean (SEM) of three independent assays of each OM sample. Samples are ordered by ascending patient age within each group (control and ALS). The right graph represents the combined mean and SEM of the control or ALS groups with the P-value for comparison of the means.
Glial inflammatory response to LPS is not altered in ALS

Mounting evidence suggests that neuroinflammation plays an important role in the degeneration of motor neurons in ALS [77]. It has been demonstrated that reactive astrocytes and microglia can release pro-inflammatory factors such as cytokines and chemokines, which are harmful to neighbouring neurons [78]. To test whether OM cells from ALS patients have an altered pro-inflammatory state and/or a modified response to inflammatory stimuli, we transduced OM cells with three different inflammation-regulated lentivirus systems [74]. As a control, OM cells were transduced with the same reporter cassette (luciferase-IRES-GFP) under the control of a constitutively promoter (SFFVp). We first transduced OM cells from healthy donors and challenged them with a pro-inflammatory stimulus, LPS. We observed efficient activation of the inflammation-regulated promoters (NFκBp, IL1/IL6p and ESELp) after LPS treatment for 6 and 27 hrs (Fig. 3A). As the largest responses to LPS were obtained with the NFκB and E-selectin promoters, we selected these reporters for subsequent experiments.

Our next goal was to ascertain if abnormal pro-inflammatory innate responses in ALS glia play a role in their toxicity to motor neurons. For this, we used the inflammation-inducible expression systems to first analyse human astrocytes overexpressing SOD1<sup>G37R</sup>, a previously published genetic model of ALS; in this model, the authors showed that co-culture with these modified astrocytes was deleterious to mouse motor neurons [18]. We thus compared astrocytes expressing either wild-type SOD1 or the mutant SOD1<sup>G37R</sup> to control astrocytes (non-transduced) after LPS treatment for 6 hrs (Fig. 3B and C). Luciferase activities were lower in astrocytes than in OM cells, indicating less pro-inflammatory response in this cell type. In addition, NFκBp and ESELp reporter activity did not increase in astrocytes expressing either wt SOD1 or mutant SOD1<sup>G37R</sup>; overall luciferase activity was actually lower in transduced astrocytes compared to that observed in control astrocytes. In the case of NFκBp, reporter activity was significantly higher in the presence of mutant SOD1 than in the presence of wild-type SOD1. In addition, LPS challenge induced a significant increase in luciferase activity in presence of mutant SOD1, but not in the presence of wild-type SOD1 (Fig. 3B). A similar effect was observed using the ESELp
reporter although the differences were not statistically significant (Fig. 3B).

We next used these inflammation-inducible reporter systems to study the inflammatory response in OM cells from healthy donors and ALS patients (Fig. 3D). Although we observed efficient activation of both NFκB (Fig. 3D) and ESELP (Fig. 3E) reporters in response to LPS treatment, no significant differences between ALS and healthy samples were observed, either in basal conditions or after LPS exposure. Thus, our results indicate that there is no alteration of the inflammatory response in OM cells from ALS samples.

**Olfactory mucosa from ALS patients shows increased inflammatory response in co-cultures with spinal cord neurons**

We next posed the question if the altered inflammatory response described for ALS might be a consequence, rather than the cause, of the abnormal interaction between neurons and glia. To address this issue, we co-cultured human astrocytes, either unmodified (control), or overexpressing wild-type SOD1 or mutant SOD1G37R with differentiated human spinal cord neurons (Fig. 4A and B). As we had observed the largest response using the NFκB reporter previously (Fig. 3), we employed it to study the effects of only neuronal co-culture on the astrocytes (Fig. 4A). Under basal conditions (in the absence of neurons), the SOD1-overexpressing astrocytes showed little change in reporter activity compared to unmodified astrocytes; neuronal co-culture significantly increased the luciferase activity in astrocytes overexpressing wild-type SOD1, and this increase was even greater in those overexpressing mutant SOD1G37R (Fig. 4A). Western blot analysis confirmed similar levels of expression of wild-type or mutant SOD1, ruling out the possibility that the different sensitivities to the neurons were because of different SOD1 levels. These results are consistent with the idea of the accumulation of wild-type SOD1 in sporadic ALS patients [79] to adopt an abnormal pathogenic conformation which may be exacerbated by overexpression or by certain point mutations.

We next applied the same methodology to measure the NFκB-mediated response in OM samples derived from healthy donors and ALS patients (Fig. 4C). Again, a significant increase in reporter activity was observed when the cells were co-cultured with spinal cord neurons, with the OM cells from ALS patients showing higher luciferase activity than those from healthy donors (Fig. 4C). As increased reporter activity in the ALS group is not observed in the absence of co-culture with neurons, we conclude that the altered glial inflammatory response in ALS is likely to be a consequence, rather than a cause, of neuronal death, which may liberate inflammatory cytokines which in turn activate NFκB-mediated responses.

**Discussion**

Multiple lines of evidence have shown the immune system, including astrocytes and microglia, to be deleterious for motor neurons in ALS. Reactive astrocytes and microglia may release pro-inflammatory factors such as cytokines and chemokines which are harmful for the neighbouring cells [78]. However, their role as the primary cause of the disease remains undetermined. Our data indicate that there is no increased innate immune response of glia in ALS: using the established model of SOD1 overexpression in human astrocytes, we did not observe increased pro-inflammatory response after LPS treatment and this result is similar when OM cells from healthy donors and those from ALS patients are compared. However, co-culture with motor neurons increases glial sensitivity to pro-inflammatory stimuli in ALS: we observed augmented NFκB-dependent reporter activity both in the SOD1-overexpressing astrocyte model as well as in OM cells from ALS patients. These results indicate that alterations in the innate immune response of glia in ALS might be a consequence of their interaction with damaged neurons rather than the cause of initial neuronal damage. Nevertheless, once sensitized, the modified pro-inflammatory response of glia in ALS could further worsen the state of neighbouring neurons. In agreement with this concept, previous work using a SOD1 transgenic mouse model demonstrated that microglia and T cells initially slow disease progression, but at later stages after accumulation of SOD1 protein, contribute to acceleration of the disease [80]. Moreover, it has been shown in both ALS patients as well as in mouse models that activation of microglia and astrocytes takes place only after distal axon degeneration [40].
The use of OM to model ALS offers certain advantages over other cell models. The non-invasive and relatively simple nasal biopsy procedure provides a patient-derived source of living cells that can be easily expanded to perform molecular analysis and functional assays. Samples can be collected not only from patients showing genetic linkage but also from sporadic cases which represent the majority of ALS victims and are more difficult to model. Most importantly, in view that sporadic ALS patients may show wide variability in disease aetiology and responses to therapy, OM cells can be obtained from living patients, offering the future possibility of personalized in vitro drug screening prior to treatment of the patient. Presently, the majority of patient-derived sALS models originate from post-mortem tissue [28, 40, 41], placing limitations on the average cellular lifespan and not offering any benefit to the donor. The advent of induced pluripotent stem cells generated from sALS patients offers an expandable cell model that can be obtained from living patients [42], but this involves a complex, time-consuming and expensive protocol. On the contrary, OM cell culture is a relatively simple and reproducible technique which can yield long-lived cultures without the need for genetic manipulations which could generate undesired non-disease-related alterations. Furthermore, OM cultures avoid the necessity for inefficient, complex and expensive protocols to differentiate neural precursors as they provide a direct source of neural cells, which, as we have observed in the present study, recapitulate ALS-specific hallmarks. Firstly, we observed that compared to healthy donor OM cells, co-culture with those derived from ALS patients results in reduced survival and aberrant morphology of spinal cord neurons, in agreement with the deleterious effect of ALS glia on co-cultured neurons previously reported [14–18]. This may be because of the generation of a toxic factor and/or decreased trophic support by the glia [26]. The latter is particularly relevant in view of the fact that our controls show that neurons exhibit drastically reduced survival in the absence of mucosa cells (control samples 'none' in Fig. 1B and [72]). Secondly, we observed good correlation between the effects obtained with OM cells from ALS patients and those from a previously published ALS model using SOD1-expressing astrocytes [18]. While LPS challenge did not result in increased NFκB-mediated response in ALS samples, when OM cells or astrocytes were co-cultured with neurons, an augmented sensitivity was observed in ALS samples that was not detected in the absence of neurons. These data indicate that while there may be no alteration of the innate immune response in cells from ALS patients, the differential death of neurons after co-culture.

**Fig. 4** Study of the inflammatory response in ALS cell models co-cultured with spinal cord neurons. Cells were transduced with reporter lentivectors encoding the luciferase gene under the control of an artificial promoter containing multiple NF-κB binding sites (NFκBp) or the constitutive spleen focus-forming virus promoter (SFFVp). Normalized luciferase activity was obtained by dividing the luciferase activity measured in relative light units (RLU) for each inflammation-responsive promoter by the mean activity of the SFFVp reporter in the same conditions. Graphs represent means and standard errors of the mean (SEM) of three independent samples. (A) Reporter activities in control human astrocytes or those overexpressing SOD1<sup>wt</sup> or SOD1<sup>G37R</sup> cultured either alone (Basal) or with spinal cord neurons for 5 days (Neurons). (B) Western blot analysis of SOD1 expression in the human astrocyte ALS cell models used in A. (C) The left graph shows reporter activities in olfactory mucosa cells from eight control donors and seven ALS patients cultured either alone (Basal) or with spinal cord neurons for 1 day. Samples are ordered by ascending patient age within each group (control and ALS). The right graph represents the combined mean and SEM of the control or ALS groups with the P-value for comparison of the means.
with ALS-derived samples may trigger an inflammatory process including activation of NF-κB pathways. Consistent with this, NF-κB activation has previously been observed in spinal cord astrocytes in ALS patients as well as in TDP-43 animal models where it was also demonstrated that the inhibition of NF-κB with Withaferin A reduced denervation in neuromuscular junctions [81, 82].

Although important advances in ALS research have been made using mutated SOD1-expressing astrocytes, this model has the disadvantage that it only represents a small fraction of genetic cases of the disease. Furthermore, transduction by the SOD1 transgene may result in overexpression of the protein at non-physiological levels or generate other disease-unrelated artefacts such as insertional mutagenesis. In the present study, to achieve a completely human model, we have examined the effect of patient OM on motor neurons derived from human foetal spinal cord. In further work, it would be interesting to compare their effect on rodent motor neuron primary cultures, which can be prepared cells that are more fully committed to the motor neuron lineage [83, 84]. To facilitate such studies, the relative homogeneity of response to different ALS OM samples with respect to controls may permit the use of pooled patient cells or perhaps even immortalized cell lines to generate more user-friendly cell models for ALS. Validation of OM as a cell model for ALS offers a new versatile tool to accelerate research and therapeutic development for this presently incurable devastating disease. Detailed characterization of OM cell models opens up the possibility of correlating genetic and functional differences which will facilitate the identification of more cellular components implicated in the disease process.

Acknowledgements

We thank Carol Marchetto and Fred Gage from the Salk Institute (La Jolla, CA) for the kind gift of the SODwt and SODG37R lentivectors. We are grateful for advice and technical aid provided by Berta Raposo and Silvia Andrade from the Flow Cytometry Service of the Centro de Biologia Molecular “Severo Ochoa”. This work was supported by grant SAF2010-22106 from the Spanish Ministry of Science and by the agency “Pedro LaEntralgo” for neurodegenerative diseases research (2007, NDG07/6). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of interest

The authors confirm that there are no conflicts of interest.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Figure S1 Survival of olfactory mucosa.

Figure S2 Immunocytochemistry of OM cells cultured in glial medium.

References

1. Rowland LP. Amyotrophic lateral sclerosis. Curr Opin Neurol. 1994; 7: 310–5.
2. Calvo AC, Manzano R, Mendonca DM, et al. Amyotrophic lateral sclerosis: a focus on disease progression. Biomed Res Int. 2014; 2014: 925101.
3. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014; 17: 17–23.
4. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 364: 362.
5. Valente SJ, Doucette PA, Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem. 2005; 74: 563–93.
6. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008; 319: 1668–72.
7. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009; 323: 1208–11.
8. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009; 323: 1205–8.
9. Greenway MJ, Alexander MD, Ennis S, et al. A novel candidate region for ALS on chromosome 14q11.2. Neurology. 2004; 63: 1936–8.
10. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011; 72: 245–56.
11. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012; 11: 323–30.
12. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72: 257–68.
13. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006; 52: 39–59.
14. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003; 302: 113–7.
15. Yamanaka K, Boillee S, Roberts EA, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci USA. 2008; 105: 7594–9.
16. Di Giorgio FP, Carrasco MA, Siao MC, et al. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci. 2007; 10: 608–14.
17. Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007; 10: 615–22.
18. Marchetto MC, Muotri AR, Mu Y, et al. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008; 3: 649–57.
19. Guegan C, Vila M, Rosoklija G, et al. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci. 2001; 21: 6569–76.

20. Watanabe M, Dykes-Hoberg M, Culetta VC, et al. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis. 2001; 8: 933–41.

21. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010; 48: 829–41.

22. Just N, Moreau C, Lassalle P, et al. High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia. Neuromuscul Disord. 2007; 17: 169–73.

23. Moreau C, Devos D, Gossot P, et al. Mechanisms of deregulated response to hypoxia in sporadic amyotrophic lateral sclerosis: a clinical study. Rev Neurol. 2010; 166: 279–83.

24. Gagliardi S, Milani P, Sardone V, et al. From transcriptome to noncoding RNAs: implications in ALS mechanism. Neurobiol Dis. 2012; 2012: 278725.

25. Bilsland LG, Sahai E, Kelly G, et al. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci USA. 2010; 107: 20523–8.

26. Redler RL, Dokholyan NV. The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog Mol Biol Transl Sci. 2012; 107: 215–62.

27. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002; 26: 459–70.

28. Schiffer D, Cordera S, Cavalla P, et al. Reactive astroglisis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci. 1996; 159: 27–33.

29. Amineser JM, Chahli C, Ince PG, et al. Glial proliferation and metabolotropic glutamate receptor expression in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2004; 63: 831–40.

30. Casula M, Iyer AM, Slipt WG, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience. 2011; 179: 233–43.

31. Wang R, Yang B, Zhang D. Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. Glia. 2011; 59: 946–58.

32. Baron P, Bussini S, Cardin V, et al. Production of monocyte chemotactic protein-1 in amyotrophic lateral sclerosis. Muscle Nerve. 2005; 32: 541–4.

33. Tateishi T, Yamasaki R, Tanaka M, et al. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J Neuroimmunol. 2010; 222: 76–81.

34. Poloni M, Facchetti D, Rai R, et al. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett. 2000; 287: 211–4.

35. Keller AF, Gravel M, Kriz J. Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells. Glia. 2005; 57: 1130–42.

36. Ferraiuolo L, Heath PR, Holden H, et al. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci. 2007; 27: 9201–9.

37. Letiembre M, Liu Y, Walter S, et al. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging. 2009; 30: 759–68.

38. Liu Y, Hao W, Dawson A, et al. Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J Biol Chem. 2009; 284: 3691–9.

39. Zhao W, Beers DR, Henkel JS, et al. Extra-cellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia. 2010; 58: 231–43.

40. Knapienberg S, Sipos J, Thau-Habermann N, et al. Altered expression of DJ-1 and PINK1 in sporadic ALS and in the SOD1 G93A ALS mouse model. J Neuropathol Exp Neurol. 2013; 72: 1052–61.

41. Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011; 29: 824–8.

42. Burkhardt MF, Martinez FJ, Wright S, et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci. 2013; 56: 355–64.

43. de Munck E, Munoz-Sanz E, Miguel BG, et al. beta-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS. Environ Toxicol Pharmacol. 2013; 36: 243–55.

44. Feron F, Perry C, McGrath JJ, et al. New techniques for biopsy and culture of human olfactory epithelial neurons. Arch Otolaryngol Head Neck Surg. 1998; 124: 861–6.

45. Ronnett GV, Leopold D, Cai X, et al. Olfactory biopsies demonstrate a defect in neuronal development in Rett’s syndrome. Ann Neurol. 2003; 54: 206–18.

46. Wolozin B, Zheng B, Loren D, et al. Beta/A4 domain of APP: antigenic differences between cell lines. J Neurosci Res. 1992; 33: 189–95.

47. Abrams MT, Kaufmann WE, Rousseau F, et al. FMR1 gene expression in olfactory neuroblasts from two males with fragile X syndrome. Am J Med Genet. 1999; 82: 25–30.

48. Feron F, Perry C, Hirning MH, et al. Altered adhesion, proliferation and death in neural cultures from adults with schizophrenia. Schizophr Res. 1999; 40: 211–8.

49. Arnold SE, Han LY, Moberg PJ, et al. Dys-regulation of olfactory receptor neuron lineage in schizophrenia. Arch Gen Psychiatry. 2001; 58: 829–35.

50. McCurdy RD, Feron F, Perry C, et al. Cell cycle abnormalities in biopsied olfactory neuroepithelium in schizophrenia and bipolar disorder using cell culture and gene expression analyses. Schizophr Res. 2006; 82: 163–73.

51. Roisen FJ, Klueber KM, Lu CL, et al. Adult human olfactory stem cells. Brain Res. 2001; 890: 11–22.

52. Murrell W, Feron F, Wetzig A, et al. Multipotent stem cells from adult olfactory mucosa. Dev Dyn. 2005; 233: 496–515.

53. Murrell W, Sanford E, Anderberg L, et al. Olfactory stem cells can be induced to express chondrogenic phenotype in a rat intervertebral disc injury model. Spine J. 2009; 9: 585–94.

54. Murrell W, Wetzig A, Donnellan M, et al. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson’s disease. Stem Cells. 2008; 26: 2183–92.

55. Au E, Roskams AJ. Olfactory ensheathing cells of the lamina propria in vivo and in vitro. Glia. 2003; 41: 224–36.

56. Doucette JR. The glial cells in the nerve fiber layer of the rat olfactory bulb. Anat Rec. 1984; 210: 385–91.

57. Feron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain. 2005; 128: 2951–60.

58. Lu J, Feron F, Ho SM, et al. Transplantation of nasal olfactory tissue promotes partial recovery in paraplegic adult rats. Brain Res. 2001; 889: 344–57.

59. Morita E, Watanabe Y, Ishimoto M, et al. A novel cell transplantation protocol and its application to an ALS mouse model. Exp Neurol. 2008; 213: 431–8.

60. Li Y, Bao J, Khatibi NH, et al. Olfactory ensheathing cell transplantation into spinal...
cord prolongs the survival of mutant SOD1 (G93A) ALS rats through neuroprotection and remyelination. *Anat Rec.* 2011; 294: 847–57.

61. Chen L, Chen D, Xi H, *et al.* Olfactory ensheathing cell neurorestoration therapy for amyotrophic lateral sclerosis patients: benefits from multiple transplantations. *Cell Transplant.* 2012; 21: S65–77.

62. Huang ZH, Wang Y, Cao L, *et al.* Migratory properties of cultured olfactory ensheathing cells by single-cell migration assay. *Cell Res.* 2008; 18: 479–90.

63. Vincent AJ, Choi-Lundberg DL, Harris JA, *et al.* Bacteria and PAMPs activate nuclear factor kappaB and Gro production in a subset of olfactory ensheathing cells and astrocytes but not in Schwann cells. *Glia.* 2007; 55: 905–16.

64. Vincent AJ, Taylor JM, Choi-Lundberg DL, *et al.* Genetic expression profile of olfactory ensheathing cells is distinct from that of Schwann cells and astrocytes. *Glia.* 2005; 51: 132–47.

65. Ozdener MH, Rawson NE. Olfactory dysfunction in neurodegenerative diseases. *Eur J Gen Med.* 2004; 1: 1–11.

66. Doty RL. Studies of olfactory dysfunction in major neurological disorders. *Adv Biosci.* 1994; 93: 593–602.

67. Ahlskog JE, Waring SC, Petersen RC, *et al.* Olfactory dysfunction in Guamanian ALS, Parkinsonism, and dementia. *Neurology.* 1998; 51: 1672–7.

68. Federico G, Maremmani C, Cinquanta L, *et al.* Mucus of the human olfactory epithelium contains the insulin-like growth factor-I system which is altered in some neurodegenerative diseases. *Brain Res.* 1999; 835: 306–14.

69. Maligian N, Abrahamson G, Sutharsan R, *et al.* Disease-specific, neurosphere-derived cells as models for brain disorders. *Dis Model Mech.* 2010; 3: 785–92.

70. Abrahamson G, Fan Y, Maligian N, *et al.* A patient-derived stem cell model of hereditary spastic paraplegia with SPAST mutations. *Dis Model Mech.* 2013; 6: 469–502.

71. Sanchez Martin C, Diaz-Nido J, Avila J. Regulation of a site-specific phosphorylation of the microtubule-associated protein 2 during the development of cultured neurons. *Neuroscience.* 1998; 87: 861–70.

72. Garcia-Escudero V, Garcia-Gomez A, Langa E, *et al.* Patient-derived olfactory mucosa cells but not lung or skin fibroblasts mediate axonal regeneration of retinal ganglion neurons. *Neurosci Lett.* 2012; 509: 27–32.

73. Cardesin A, Alobid I, Benitez P, *et al.* Barcelona Smell Test - 24 (BAST-24): validation and smell characteristics in the healthy Spanish population. *Rhinology.* 2006; 44: 83–9.

74. Garaulet G, Alfaranca A, Torrente M, *et al.* IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritis. *Mol Ther.* 2013; 21: 119–30.

75. Garcia-Escudero V, Garcia-Gomez A, Garzini R, *et al.* Prevention of senescence progression in reversibly immortalized human ensheathing glia permits their survival after deimmortalization. *Mol Ther.* 2010; 18: 394–403.

76. Koechling T, Khlaique H, Sundstrom E, *et al.* A culture model for neurite regeneration of human spinal cord neurons. *J Neurosci Methods.* 2011; 201: 346–54.

77. Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathogenesis of amyotrophic lateral sclerosis. *J Neuroimmune Pharmacol.* 2013; 8: 888–99.

78. Phani S, Re DB, Przedborski S. The role of the innate immune system in ALS. *Front Pharmacol.* 2012; 3: 150.

79. Bosco DA, Morfini G, Karabacak NM, *et al.* Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. *Nat Neurosci.* 2010; 13: 1396–403.

80. Henkel JS, Beers DR, Zhao W, *et al.* Microglia in ALS: the good, the bad, and the resting. *J Neuroimmune Pharmacol.* 2009; 4: 389–98.

81. Miglioli A, Piva R, Atzori C, *et al.* c-Jun, JNK/SAPK kinases and transcription factor NF-kappaB are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis. *J Neuropathol Exp Neurol.* 1997; 56: 1314–22.

82. Swarup V, Phaneuf D, Dupre N, *et al.* Deregression of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. *J Exp Med.* 2011; 208: 2429–47.

83. Anderson KN, Potter AC, Piccenna LG, *et al.* Isolation and culture of motor neurons from the newborn mouse spinal cord. *Brain Res Brain Res Protoc.* 2004; 12: 132–6.

84. Cheng S, Shi Y, Hai B, *et al.* Culture of motor neurons from newborn rat spinal cord. *J Huazhong Univ Sci Technolog Med Sci.* 2009; 29: 413–6.